EMA Establishes Drug Identification Task Force

News
Article

The agency is enlisting members of European pharmaceutical associations and industry representatives to participate in IDMP task force.

 

The European Medicines Agency (EMA) has gathered representatives from European Union national authorities, software vendors, and other organizations to create a task force that will develop a strategy for the implementation of international standards for the identification of medicinal products (IDMP) in the EU. European pharmacovigilance legislation requires the use of common standards in the EU to identify and exchange information on medicines.

The International Organization for Standardization (ISO) developed IDMP standards to establish data elements, formats, and terminologies for the unique identification of drugs and the exchange of information on medicines, including pharmaceutical dosage forms, routes of administration, packaging, and active substances. The ISO standards were finalized in 2012 and implementation guidelines are expected to be published in 2016. According to EMA, the ISO standards will simplify the exchange of information between international regulatory authorities, therefore supporting the development of electronic health records and improving the safety monitoring of drugs.

Organizations interested in participating in the task force must express their interest to EMA by Mar. 6, 2015.

Source: European Medicines Agency

 

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.